MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

42.01 2.51

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.98

Max

43.64

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+31.22% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-639K 3.2B
Eelmine avamishind	39.5
Eelmine sulgemishind	42.01

Uudiste sentiment

By Acuity

50%

187 / 370 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. jaan 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. jaan 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. jaan 2026, 21:43 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9. jaan 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9. jaan 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9. jaan 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9. jaan 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9. jaan 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9. jaan 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9. jaan 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9. jaan 2026, 19:58 UTC

Omandamised, ülevõtmised, äriostud

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9. jaan 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9. jaan 2026, 19:38 UTC

Omandamised, ülevõtmised, äriostud

Wolters Kluwer Acquires StandardFusion >WTKWY

9. jaan 2026, 19:31 UTC

Tulu

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9. jaan 2026, 19:28 UTC

Tulu

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9. jaan 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9. jaan 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

9. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. jaan 2026, 17:19 UTC

Market Talk

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9. jaan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. jaan 2026, 17:07 UTC

Market Talk

McDonald's Promotions Appear Successful -- Market Talk

9. jaan 2026, 17:06 UTC

Market Talk

Oil Futures on Track for Weekly Gains -- Market Talk

9. jaan 2026, 17:05 UTC

Tulu

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9. jaan 2026, 16:57 UTC

Market Talk

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9. jaan 2026, 16:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. jaan 2026, 16:46 UTC

Market Talk

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

31.22% tõus

12 kuu keskmine prognoos

Keskmine 54.09 USD 31.22%

Kõrge 62 USD

Madal 44 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

187 / 370 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.